This medication is an anticoagulant, which is used for reducing the risk of strokes and blood clots in patients with atrial fibrillation who have no problems with their heart valve (nonvalvular atrial fibrillation).
Contraindicated in patients with active pathological bleeding and hypersensitivity. It should not be co-administered with unfractionated heparin (UFH), enoxaparin and dalteparin, fondaparinux, and oral anticoagulants.
PO- The recommended dose is 5 mg twice daily.
Decrease dose to 2.5 mg PO BID in following conditions
- while coadministrating strong dual inhibitors.
- age ≥ 80 years
- body weight ≤ 60 kg
- serum creatinine ≥ 1.5 mg/dL
It comes as a tablet to take by mouth, with or without food.
• Caution should be exercised in patients with history of kidney or liver problems, bleeding problems, any allergy, who are taking other medications, children, during pregnancy and breastfeeding.
• Patients already taking 2.5 mg BID, avoid coadministration with strong dual inhibitors.
• Discontinuing eliquis in patients without adequate continuous anticoagulation increases risk of stroke.
The most common side effect is bleeding. Other side effects include bleeding in the stomach, intestines, brain, and eyes; the bleeding may be fatal.
Avoid excess dosage.
Apixaban should be stored at room temperature between 15 C to 30 C (59 F to 86 F).
Subscribe to our Free Newsletters!